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Introduction
Technological progress in the field of biomedical research has 
resulted in an increased utilization of platforms generating 
information on a system-scale, e.g. genome, transcriptome and 
proteome. As researchers are typically willing and often required 
to share their data collections, the availability of ‘big data’ is 
expanding rapidly. At this moment, the NCBI Gene Expression 
Omnibus (GEO), a public repository of transcriptome profiles, 
holds over 2 million individual transcriptome profiles from more 
than 76,000 studies (“Home - GEO - NCBI”, 2016). This large 
amount of available transcriptomic data provides major opportuni-
ties as well as challenges to researchers. Identification of differ-
ential gene expression in healthy versus diseased individuals, for 
example, has the potential to increase our understanding of the 
disease process, can lead to the identification of novel disease 
biomarkers or to the recognition of potential therapeutic targets. 
However, utilization of the available system-scale information can 
be challenging, since data repositories often lack the analytical and 
visualization tools needed for data assessment and interpretation. 
For this reason, proper analysis relies on elevated bioinformatics 
skills.
To overcome the challenges faced when analyzing transcriptomic 
data, we previously developed a web application called gene 
expression browser (GXB), which makes datasets more accessible 
and interactive (Speake et al., 2015). The application graphically 
visualizes gene expression data in bar chart or box plot 
representation and is capable of dynamically changing its interface 
views upon user input. GXB allows users to upload microarray 
data, add data annotations, which enables overlay of clinical 
data, explore gene rank lists based on their differential expres-
sion patterns between groups, view the data on a gene-by-gene 
basis and compare different datasets and diseases. These capa-
bilities stimulate the acquisition of new knowledge from public 
datasets, as demonstrated by the first paper that employed 
GXB to identify a previously unknown role of a specific transcript 
during immune-mediated processes (Rinchai et al., 2015).
In recent years, a large number of transcriptional studies have 
been conducted with the aim to characterize breast cancer on a 
genetic basis. GEO holds about 1297 datasets relating to breast 
cancer. One of the main impacts gene expression profiling has 
had on our understanding of breast cancer has been through the 
classification of breast cancer into intrinsic molecular subtypes 
(IMS). Three main methods have been described to achieve this, 
which have the same subtypes, but actually use different gene sets 
to stratify the patients (Hu et al., 2006; Parker et al., 2009; Sorlie 
et al., 2003). Four major IMS of breast cancer have been identi-
fied: Luminal A, Luminal B, HER2-enriched and Basal-like. A less 
common molecular subtype called Claudin-low has been 
characterized at a later time point (Prat et al., 2010). Stratified 
IMS groups present critical differences in incidence, survival 
and response to treatment, and most importantly add prognostic 
information that is not provided by classical stratifications, like 
estrogen receptor status, histologic grade, tumor size, and node 
status (Parker et al., 2009).
Recent breakthroughs in the field of cancer immunotherapy 
and especially the application of checkpoint blockade inhibi-
tors has ignited a fierce drive to understand the genetic basis for 
the huge differences observed between patients with different 
immune phenotypes. Several papers have shown that expres-
sion profiles are able to distinguish between those patients 
that have an active immune environment and those that do not 
(Galon et al., 2013; Herbst et al., 2014; Ji et al., 2012; Ribas 
et al., 2015; Wang et al., 2013). A clear correlation can be seen 
both regarding prognosis (survival) and prediction of therapeutic 
effectiveness of immune regulatory therapies. The expression of 
genes observed in association with tissue-specific destruction in a 
broader context, defined as the immunological constant of rejection 
(ICR), can distinguish between breast cancer patients with differ-
ent prognosis. This immunological classification is based on the 
consensus clustering of ICR genes (Galon et al., 2013), e.g. genes 
underlying Th1 polarization, related chemokines, adhesion mol-
ecules and cytotoxic factors, in combination with immune regula-
tory genes IDO1 and FOXP3, PDCD1, CTLA4 and CD274/PD-L1 
(Figure 1A) (Bedognetti et al., 2015). In Miller et al. (2016), a 
novel survival-based immune classification system was devised 
for breast cancer based on the relative expression of immune 
gene signatures that reflect different effector immune cell sub-
populations, namely antibody-producing plasma B cells (the B/P 
metagene), cytotoxic T and/or NK cells (the T/NK metagene), 
and antigen-presenting myeloid/dendritic cells (the M/D meta-
gene). The system defines a tumor’s immune subclass based on its 
survival-associated immunogenic disposition status (IDS), which 
discriminates between poor immunogenic disposition (PID), weak 
immunogenic disposition (WID) and favorable immunogenic 
disposition (FID). The ability of IDS to distinguish patients with 
differential prognosis is dependent on the tumor’s immune benefit 
status (IBS), which is defined by IMS and the expression of cell 
proliferation markers. The IBS classification segregates immune 
benefit-enabled (IBE) and immune benefit-disabled (IBD) tumors. 
In IBE tumors, but not IBD tumors, FID status confers a protec-
tive survival benefit compared to WID and PID status (Figure 1B) 
(Miller et al., 2016; Nagalla et al., 2013). In this data note, we 
demonstrate the use of GXB to evaluate cancer gene expression 
across immunologic classifications of breast cancer.
Since the amount of possible datasets to be included in GXB is 
enormous, we chose to start with the GEO datasets underlying the 
            Amendments from Version 1
The manuscript was revised according to referees’ suggestions. 
For clarity, names of datasets have been renamed to reflect the 
institution that has generated the data, both in the manuscript and 
the online GXB browser. The first example case of utilization of 
GXB has been adapted so the different strategies to explore the 
data are better represented. In addition, the existence of different 
probes for single transcripts is pointed out and explained in this 
example. As we recognize that we use quite a lot of abbreviations 
corresponding to the different classifications applied to the 
breast cancer datasets, we created an extra table (Table 2) to 
summarize the variables and categorizations. 
See referee reports
REVISED
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Figure 1. Basis of  ICR and  IDS/IBS classifications and prognostic value.  (A) Consensus clustering based on ICR genes segregates 
breast cancer patient in four different groups: ICR1, 2, 3 and 4. Patients with tumors categorized as ICR4 have the highest expression of 
the ICR gene signature and have a better prognosis compared with other ICR groups. (B) Immune metagene model based on the relative 
expression of immune metagenes (B/P, T/NK and M/D) distinguishes PID, WID and FID tumors (horizontal axis: genes, vertical axis: individual 
cases). This classification has prognostic value in IBE tumors, and not in IBD tumors. Diagrams are based on Hendrickx et al., 2017 (A) 
and Miller et al., 2016 (B). This figure is for explanatory purposes only and does not serve as a demonstration of the GXB web application. 
ICR, Immunologic Constant of Rejection; IBE/D, Immune Benefit Enabled OR Disabled; F/P/WID, Favorable OR Poor OR Weak Immune 
Disposition.
immunologically classified breast cancer datasets by (Miller et al., 
2016). In Hendrickx et al. (2017), these same datasets were clas-
sified according to ICR. This will allow us to share our immune 
related classifications in a comprehensible way and allow oth-
ers to reuse them. A harmonization effort of the other available 
clinical data had been undertaken and should help the 
downstream analysis of the expression data. Therefore, gathering 
these datasets with their detailed study and sample information 
will facilitate the identification of clinically-relevant genetic 
signatures for biomarker and/or therapeutic purposes.
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In this data note, using GXB, we have made available 
a curated compendium of 13 public datasets relevant to human 
breast cancer, representing a total of 2142 cases.
Methods
Selection of breast cancer datasets
The starting point of our selection of breast cancer datasets are 
the patient cohorts included in the multi-study breast cancer 
database described by Nagalla et al. (2013). These 13 
NCBI GEO datasets (GEO accession numbers: GSE45255, 
GSE2034, GSE5327, GSE12093, GSE9195, GSE11121, GSE1456, 
GSE2603, GSE6532, GSE7390, GSE7378 and GSE4922) 
resulted in 2142 cases initially uploaded in GXB. 22 of these 
cases reflect data from breast cancer cell lines and were therefore 
excluded from our data collection. A total of 1839 cases repre-
sent primary invasive breast tumors sampled at the time of sur-
gical resection without prior neoadjuvant treatment and were 
therefore annotated with survival data, IMS, IBS, IDS and 
ICR status (Hendrickx et al., 2017; Miller et al., 2016). 281 
of the cases did not fulfill these criteria and were therefore not 
annotated. Of note, 115 cases of original meta-cohort used 
Nagalla’s study (n=1954) were not shared within GEO, but 
shared within other platforms (caArray and ArrayExpress). For 
this reason, these samples were not included in our GXB 
collection (Figure 2).
The datasets that comprise our collection are listed in Table 1 
and can be searched interactively in GXB. All GEO datasets 
consist of unique cases with the exception for 36 cases from 
NUH Singapore, which are both present in the Bordet Radcliff 
NUH (GSE45255) dataset and the Uppsala and Singapore 
(GSE4922) dataset.
Data of the 1839 GEO-cases annotated with survival data that 
were previously combined and used in the Nagalla study, have 
been uploaded to GXB in the dataset “Nagalla 2013 reconstituted 
public dataset”.
Dataset upload into GXB
All datasets were downloaded from NCBI GEO in SOFT file 
format and were uploaded into GXB with the exception of the 
Guy’s hospital dataset (GUYT2; GSE9195). Expression data 
in the SOFT file of this dataset was expressed as fold change. 
Therefore, we had to revert to reprocessing of the CEL files found 
attached to the GSE on GEO. In this case, the cell files were 
read into R (v3.2.2) using the ‘affy’ package (v1.50.0). Data was 
normalized using the RMA (Robust multichip averaging) and 
gene annotation data was added using the hgu133plus2.db 
package (v3.2.3).
GSE records containing data generated with different or 
multiple platforms have been split by platform using the import 
process of GXB. GSEs containing data from both clinical as 
in vitro origin (GSE2603) have been split manually using the 
GXB Graphical interface.
Metadata of the different studies was added to GXB both from 
the descriptive information found on GEO or from the method 
Figure 2. Schematic representation of dataset selection and annotation. Breast cancer cases included in 13 NCBI GEO datasets were 
uploaded in GXB (n=2142). 22 cases described data from breast cell lines and were excluded from our data collection. We annotated 1839 
cases with survival data, IMS, IBS, IDS and ICR status. 281 cases were either neoadjuvant treated, did not represent a primary invasive 
tumor, were not sampled at the time of surgery or without available survival data and were therefore not annotated. The total collection 
includes 1839 cases from the original cohort described in Nagalla et al. (2013) (n=1954). Of note, 115 cases of this cohort are not included 
in our collection as these were not shared via GEO. *251/1839 cases have been classified for IMS “Normal-like”. IDS is not applicable for 
normal-like breast cancer tissue; therefore, IDS is non-classified for these samples. DMFS, Distant Metastasis Free Survival; GXB, Gene 
Expression Browser; IMS, intrinsic molecular subtype; IBS, immune benefit status; IDS, immune disposition status; ICR, immunologic constant 
of rejection.
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Table 1. List of datasets uploaded to GXB.
Dataset Platforms Diseases Number of samples GEO ID References
Bordet Radcliffe NUH dataset -  
GSE45255.GPL96
Affymetrix Human Genome 
U133A Array
Mixed Breast 
Cancer Types 139 GSE45255 (Nagalla et al., 2013)
Erasmus Medical Center (EMC) 
dataset 1 - GSE2034.GPL96





286 GSE2034 (Wang et al., 2005)
Erasmus Medical Center (EMC) 
dataset 2 - GSE5327.GPL96





58 GSE5327 (Minn et al., 2007)
Europe and Cleveland (EMCT) 
dataset - GSE12093.GPL96
Affymetrix Human Genome 
U133A Array
ER + Breast 
Cancer 136 GSE12093 (Zhang et al., 2009)
Guy’s hospital dataset (GUYT2) -  
GSE9195.GPL570.fCEL
Affymetrix Human Genome 
U133 Plus 2.0 Array
ER+ Breast 
Cancer 77 GSE9195 (Loi et al., 2008)
Johannes Gutenberg University 
(MAINZ) dataset - GSE11121.GPL96
Affymetrix Human Genome 
U133A Array
LN- Breast 
Cancer 200 GSE11121 (Schmidt et al., 2008)
Karolinska (STO) dataset - +GPL97
Affymetrix Human Genome 
U133A Array & Affymetrix 
Human Genome U133B 
Array
Mixed Breast 




Affymetrix Human Genome 
U133A Array
Mixed Breast 
Cancer Types 99 GSE2603 (Minn et al., 2005)
Nagalla 2013 reconstituted public 
dataset
Affymetrix Human Genome 
U133A Array & Affymetrix 
Human Genome U133A2 
Array & Affymetrix Human 
Genome U133 Plus 2.0 
Array
Mixed Breast 
Cancer Types 1839 multiple (Nagalla et al., 2013)
Guys hospital (GUYT) dataset - 
GSE6532.GPL570
Affymetrix Human Genome 
U133 Plus 2.0 Array
ER+ Breast 
Cancer 87 GSE6532 (Loi et al., 2007)
John Radcliff Hospital (OXFU, OXFT) 
dataset - GSE6532.GPL96 +GPL97
Affymetrix Human Genome 
U133A & U133B Array
ER+ Breast 
Cancer 327 GSE6532 (Loi et al., 2007)
TRANSBIG (TBIG) dataset - 
GSE7390.GPL96













Cancer 54 GSE7378 (Zhou et al., 2007)
Uppsala and Singapore dataset -  
GSE4922.GPL96 +GPL97
Affymetrix Human Genome 
U133A & U133B Array
Mixed Breast 
Cancer Types 289 GSE4922 (Ivshina et al., 2006)
sections of the publications linked to these datasets. Short links to 
PMID (Pubmed) and GEO records were added.
Construction of the Nagalla’s dataset
The constitution of the complete cohort has previously been 
described by (Nagalla et al., 2013). The dataset “Nagalla 2013 
reconstituted public dataset” available in GXB contains only 
the samples that were publicly available via GEO. Briefly, raw 
data (CEL files) were extracted from GEO. The array platforms 
employed for these 13 datasets were Affymetrix U133A, U133A2, 
and U133 PLUS 2.0 gene chips; the 22,268 probe sets that are 
present in all platforms were included in the gene expression file. 
Data were MAS5.0 normalized using the justMAS function in the 
simpleaffy library from Bioconductor (Gentleman et al., 2004) 
using a trimmed mean target intensity of 600 without background 
correction. COMBAT empirical Bayes method was used to correct 
for batch effects (Johnson et al., 2007).
Clinical data annotation
Gene expression data is accompanied with clinical data in 
CSV file format. Gene expression data and clinical data are cou-
pled to the sample via variable “Sample ID”. We annotated a total 
of 1839 cases with 10-year survival (time and event), IBS (IBE, 
IBD), IDS (PID, WID and FID) (Miller et al., 2016) and ICR (ICR1, 
ICR2, ICR3 and ICR4) immune classifications (Hendrickx et al., 
2017) (Figure 2, Table 2). IMS (i.e., Basal-like, HER2-enriched, 
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DMFS 10Y EVENT 13
DMFS 10Y TIME 13
Disease free survival event 11
Disease free survival time 11
Distant metastasis free survival event 6
Distant metastasis free survival time 6
Age at initial pathologic diagnosis 8
Lymph node status 8
ER status 8
PR status 5
Histology differentiation grade 7
Tumor size 8
Pathology T Stage 8
Type treatment, bone metastasis event, 
bone metastasis free survival time, breast 
cancer cause of death, HER2 status, 
histologic diagnosis, lung metastasis 
event, lung metastasis free survival 
time, lung metastasis gene expression 
signature status, vital status, angio 
invasion indicator, disease specific 
survival time, genetic grade signature 
status sws classifier, GGI indicator, lymph 
nodes examined count, number of lymph 
nodes positive, lymphocyte infiltration, 
molecular subtype, NPI, overall survival, 
p53 mutation status, probability by 
sws classifier, RFS 5Y EVENT, risk AOL 
indicator, risk NPI indicator, risk SG, risk 




Intrinsic Molecular Subtype 
(IMS)
Normal-like (Normal); HER2-enriched 
(Her2); Basal-like (Basal); Luminal A 
(LumA); Luminal B (LumB); Claudin 
low (ClaudinLow)
(Hu et al., 2006)
Immune Benefit Status (IBS)
Immune Benefit-Enabled (IBE); 
Immune Benefit-Disabled (IBD)
(Miller et al., 2016;  
Nagalla et al., 2013)
Immunogenic Disposition 
Status (IDS)
Poor Immunogenic Disposition (PID); 
Weak Immunogenic Disposition (WID); 
Favorable Immunogenic Disposition 
(FID)
(Miller et al., 2016;  
Nagalla et al., 2013)
Immunologic Constant of 
Rejection (ICR) ICR1; ICR2; ICR3; ICR4
(Galon et al., 2013; 
Hendrickx et al., 2017)
Luminal A and Luminal B) were defined using the Single Sample 
Predictor (SSP) algorithm by Hu (Hu et al., 2006) utilized by 
(Fan et al., 2006). Claudin-low tumors were identified using 
the method of (Prat et al., 2010). Of the 1839 samples, 251 
samples were “Normal-like” in IMS classification. Therefore, 
these samples are not classified according to IDS. For the sepa-
rate dataset containing samples of in vitro origin (GSE2603), sur-
vival annotations and immune classifications are not applicable. 
A final 281 cases were not annotated and non-classified, since for 
these cases either samples were not taken at the time of surgical 
resection, were neoadjuvant-treated or cases were not annotated 
with distant metastasis free survival (DMFS) time and event.
To enable comparisons between datasets and to facilitate 
efficient data analysis, the clinical data was harmonized to reflect a 
nomenclature similar to that of The Cancer Genome Atlas (TCGA). 
Clinical variable names and availability in datasets are listed in 
Table 3. In general, variable values have been replaced by descrip-
tive values (e.g. “1” and “0” are replaced by “ER+” and “ER-”, 
respectively). For disease free survival, variable values have been 
adapted to “DiseaseFree” or “Recurred/Progressed”, and for dis-
tant metastasis survival to “DistantMetastasisFree” and “Distant-
Metastasis”. Numeric values of variable “tumor size” have been 
converted to units in cm for all datasets. This variable was used to 
generate the additional variable pathology T stage according to the 
7th edition of the AJCC staging system for breast cancer (Edge & 
Compton, 2010). For tumors with a diameter larger than 5 cm, 
pathology T stage could be either T3 or T4, therefore value “T3/T4” 
has been assigned to these cases.
Standardized clinical datasets can be found in the ‘downloads’ tab 
in GXB under the heading “additional files”. All datasets start with 
the following 21 clinical variables in fixed order: “sample.ID”, 
“array sample id”, “sample title”, “series”, “IMS”, “IBS”, “IDS”, 
“ICR”, “DMFS_10Y_EVENT”, “DMFS_10Y_TIME”, “disease 
free survival event”, “disease free survival years”, “distant met free 
survival event”, “distant met free survival”, “age at initial patho-
logic diagnosis”, “lymph node status”, “ER status”, “PR status”, 
“histology differentiation grade”, “tumor size cm”, and “pathology 
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T stage”. In case one of these variables is not available in a 
specific dataset, values in this column are all NA.
Group sets for IBS/IDS, ICR cluster, Lymph Node (LN) Status, 
IMS, Histological grade, stage and Estrogen Receptor (ER) sta-
tus were defined with matching differential gene expression rank 
lists. Rank lists are based on differential gene expression between 
two relevant groups for each group set: IBD-FID vs IBE-FID 
(IBS/IDS); ICR1 vs ICR4 (ICR1/ICR4); LN+ vs LN- (LN status); 
G1 vs G3 (histological grade); ER+ vs ER- (ER status). For IMS, 
no rank list was generated, as this variable is not ordered. For 
tumor stage, no rank list was generated because the spread of 
samples between categories was small (R scripts for this 
harmonistaion have been made available on Github.).
Dataset demonstration
Utilization of GXB
The GXB software has been described in detail in a recent 
publication (Speake et al., 2015). This custom software inter-
face provides users with a means to easily navigate and filter the 
dataset collection available at http://breastcancer.gxbsidra.org/
dm3/landing.gsp. A web tutorial is also available online: http:// 
breastcancer.gxbsidra.org/dm3/tutorials.gsp#gxbtut.
Example case: Expression of HLA-G across ICR groups
In GXB, users can search interactively for a specific gene of 
interest. Differential expression across different group sets 
can be observed in the graphical interface, either in bar or box 
plots. For illustrative purposes, we choose to evaluate the 
abundance of the HLA-G transcripts across ICR groups.
HLA-G is a non-classical class I gene of human Major His-
tocompatility Complex that is primarily expressed on fetal 
derived placental cells (Ellis et al., 1990). In contrast to its 
classical counterparts, HLA-G does not initiate immune 
responses, but instead has immunosuppressive effects (Naji et al., 
2014; Rouas-Freiss et al., 1997). Expression of HLA-G has been 
reported in a variety of cancers, including breast cancer, and has 
been assigned a role in tumor immune escape (Naji et al., 2014; 
Rouas-Freiss et al., 1997; Swets et al., 2016; Zeestraten et al., 
2014).
Concerning its role in tumor immunity, it may be of interest 
to investigate whether HLA-G expression is elevated in breast 
tumors of specific immune phenotypes. The ICR gene signature 
segregates breast tumors into four immune phenotype groups 
based on the expression of genes underlying immune-mediated 
tissue-specific destruction, with ICR1 having the lowest and ICR4 
the highest expression of this signature (Bedognetti D et al., 
in press).
To compare HLA-G expression across ICR groups using the 
breast cancer datasets uploaded to GXB, we start by selecting 
a dataset. Users can decide to first explore the Nagalla 2013 
dataset containing the total of 1839 annotated cases from all 
uploaded datasets to define trends to subsequently check their 
consistency over the different datasets. Alternatively, users can 
first explore the individual datasets. After opening one of the 
datasets: 1) the gene of interest, HLA-G, can be identified using 
the search box in the upper left corner of the user interface. Upon 
selection of “HLA-G” in the left panel, the central panel displays 
the expression values of this gene for all samples as a bar chart. 
For some of the transcripts, as is the case for the HLA-G tran-
script, multiple probes are available. Probe ID can be displayed 
by clicking “Tools” in the central panel and clicking “Show Probe 
ID” in the dropdown list. In this example, which is for illustrative 
purposes only, we selected probe ID 211528_X_AT at random. 
2) Sample grouping is default as “All sample”, it is changed by 
selecting “Immunologic Constant of Rejection” and 3) plot type 
is set to “Box Plot” in drop down menus in the central panel. The 
central panel now presents a graphical display of the observed 
abundance of HLA-G transcripts in breast cancer samples 
across the different ICR groups, each sample is represented by 
a single point in a boxplot (Figure 3A). A tendency of increased 
HLA-G expression in groups with the highest expression of 
ICR genes can be observed. 4) To verify whether this trend can 
also be observed in other breast cancer datasets, GXB’s “Cross 
Project View” is used. By selecting “Cross Project View” in the 
“Tools” drop-down menu located in the top right corner of the user 
interface, a list of available datasets/projects appears in the left 
pane. By consecutive selection of single datasets, box plots with 
HLA-G transcripts across ICR groups are displayed for each 
individual dataset.
Each of the boxplots corresponding to the 13 datasets show a 
similar pattern, indicating an increased HLA-G expression in 
breast tumors with a high expression of ICR genes (representa-
tive plots are shown in Figure 3B). In the combined dataset con-
taining the total of 1839 annotated cases from these datasets, this 
trend is also observed (Figure 3B). From a biological perspective, 
increased expression of an immunosuppressant in an immunologi-
cally active tumor would be in line with our current view of the 
tumor microenvironment. Pro-inflammatory tumor environments, 
as observed in ICR4 tumors, also show counter regulatory mech-
anisms to suppress the immune system (Bedognetti et al., 2015; 
Galon et al., 2013).
This observation made by exploring transcriptome data in 
GXB provides an interesting starting point for further analysis. 
Statistical analysis of this potential association is required and, 
of course, the clinical relevance of the observed difference in 
abundance of transcripts should be determined. Most impor-
tantly, the functional relevance of HLA-G expression depends on 
its interaction with inhibitory receptors including ILT2, ILT4 and 
KIR2DL4 (LeMaoult et al., 2005). Therefore, combined analy-
sis of both HLA-G and these inhibitory receptors is suggested in 
future analyses.
This example illustrates the convenience of exploring gene 
expression data in GXB. The browser facilitates intuitive naviga-
tion and visualization of gene expression across different group 
sets.
Differential gene expression between IBS/IDS subgroups
The breast cancer datasets uploaded in GXB are provided with 
a rich context of immune classifications and clinical parameters. 
As opposed to start a search with a specific gene of inter-
est, as presented in the HLA-G example case, differential gene 
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expression between groups of interest can be explored in 
GXB by evaluation of gene rank lists. Here, we demonstrate the 
use of GXB to explore differential gene expression across IBS/IDS 
groups.
The IDS group set is based on an immune metagene model 
segregating breast tumors in groups of different immunogenic 
dispositions: PID, WID and FID (Nagalla et al., 2013). The 
prognostic value of this classification is dependent on the molec-
ular subtype and the proliferative capacity of the tumor, hereby 
segregating tumors in IBE and IBD groups, with and without 
prognostic value of the IDS, respectively. Since the hypothesis is 
that IBE-FID tumors confer metastasis-protective potential and 
IBD-FID tumors do not, transcriptional differences between 
these specific subgroups are of particular interest and have 
systematically been analyzed by Miller et al. (2016).
Figure  3.  Illustrative  example  of  abundance  of  HLA-G  transcripts  across  ICR  groups  in  multiple  breast  cancer  datasets  in  GXB. 
(A) Cross Project View in GXB showing HLA-G expression across ICR groups. ICR represents the immune gene signatures observed in 
association with tissue-specific destruction. In this view of GXB, expression of HLA-G can be visualized across projects listed on the left. 
(B) Boxplots of HLA-G expression across ICR groups of three additional representative datasets selected from the dataset collection and the 
complete dataset including all annotated cases (right bottom plot). Plots indicate an increased HLA-G expression in breast tumors with a high 
expression of ICR genes. ICR, Immunologic Constant of Rejection.
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Figure 4. GXB overview of expression of genes with known roles in tumor immunology across IBS/IDS subgroups in reconstituted 
Nagalla’s breast cancer dataset. (A) Expression values of CD8 and CD19, indicators of immune cell infiltration, are similar in IBD-FID and 
IBE-FID groups, indicating equal immune cell infiltration in these subgroups. (B) Expression values of CXCL10, GNZB, IFNG and STAT1, 
markers of immune functional orientation, are increased in the IBE-FID group compared with IBD-FID, indicating a differential functional 
orientation of the immune infiltrate between IBD-FID and IBE-FID tumors. IBE/D, Immune Benefit Enabled OR Disabled; F/P/WID, Favorable 
OR Poor OR Weak Immune Disposition.
The Nagalla 2013 reconstituted dataset containing all anno-
tated cases of this GXB breast cancer instance (n=1839) is used 
to explore differential gene expression between IBE-FID and 
IBD-FID tumors in GXB. Group set “Immune Benefit Status” 
is selected and corresponding gene rank list “IBD-FID vs IBE-
FID” will load in the left panel by default. Filtering for specific 
immune gene categories, e.g. cytokine and chemokine ligands, 
cytokine and chemokine receptors, B and T cell signaling, and 
antigen presenting cell processing, is possible by selecting gene 
list category in the rank list menu. Exploring the expression of 
genes with known roles in tumor immunology reveals two impor-
tant observations: 1) markers of immune cell infiltration, including 
CD8, CD3, CD19 and CD2, show similar expression in IBD-FID 
and IBE-FID subgroups (Figure 4A); while (2) markers of immune 
functional orientation, including CXCL10 (tissue rejection chem-
okine), GZMB (cytotoxic effector molecule), INFG and STAT1 
(Th1 polarization), show differential expression across IBD-FID 
and IBE-FID groups (Figure 4B). A comprehensive statistical 
analysis of expression of these and other immune-related genes 
confirmed these observations, suggesting that while the composi-
tion of the immune infiltrate is similar in these tumors, the func-
tional molecular orientation determines the metastasis-protective 
phenotype (Miller et al., 2016).
This demonstration indicates that GXB allows for easy and 
efficient visualization of differential gene expression between sub-
groups. Subsequently, elaborate statistical analysis is required to 
confirm the differences in gene expression observed in GXB.
Overview of breast cancer immune classifications in GXB
Since this GXB data collection is provided with multiple immune 
classifications of breast cancer, it is interesting to visualize the 
relationship between these classifications in GXB. The overlay fea-
ture in GXB can be used to visualize the assignment of different 
classifications to individual samples simultaneously.
To illustrate this overlay option, we choose to select the 
Erasmus Medical Center dataset 2 (EMC2) with CXCL9 expres-
sion, as this is one of the chemokines included in the ICR gene 
signature. Graphical representation in GXB is set to bar plot and 
group set ICR is selected. As anticipated, the CXCL9 expres-
sion gradually increases from ICR1-ICR4. The drop down menu 
“Overlays” is used to add multiple layers of additional variables, 
“IBS”, “IDS” and “IMS”. Boxes underneath the individual bars 
(each bar represents a single case) display the assigned classifi-
cations (Figure 5A). When comparing IBS classifications across 
ICR groups, it is evident that IBE tumors are frequently assigned 
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Figure 5. Overlay of immunologic classifications in breast cancer as evaluated in GXB. (A) Bar graph showing CXCL9 expression in 
individual samples from Erasmus Medical Center (EMC) dataset 2 split by ICR (single bar represents single case). Overlay of additional 
variables IBS, IDS and IMS is shown (http://breastcancer.gxbsidra.org/dm3/miniURL/view/Lv). (B) Frequency plot showing number of breast 
cancer cases across IBS/IDS subgroups split by ICR cluster. ICR, Immunologic Constant of Rejection; IBE/D, Immune Benefit Enabled OR 
Disabled; F/P/WID, Favorable OR Poor OR Weak Immune Disposition.
to the higher ICR clusters, ICR3 and ICR4, while IBD tumors 
tend to concentrate to the clusters with a low expression of the 
ICR signature (ICR1, ICR2) (Figure 5A). This result is consist-
ent with our previous observations: pathways that distinguish IBE 
and IBD are associated with the immune functional orienta-
tion of the tumor, and genes in these same pathways are crucial 
components of the ICR signature (Bedognetti et al., 2015; 
Miller et al., 2016).
IDS relates to the ICR classification in a similar manner. FID 
tumors are mostly assigned to ICR4, while WID tumors are fre-
quently classified to intermediate clusters (ICR2 and ICR3), 
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and PID tumors prevail in the ICR1 cluster (Figure 5A). This 
observation is also in line with our expectations, the IDS clas-
sification is based on an immune metagene model that relies on 
immune gene subclusters that reflect the relative abundance 
of tumor-infiltrating immune cells (Nagalla et al., 2013). As 
markers of immune cell infiltration are also included in the ICR 
signature, IDS is closely associated with ICR.
For a more comprehensive overview of the relationship between 
different immune classifications in breast cancer, the overlay 
of immune classifications was evaluated in the Nagalla 2013 
reconstituted public dataset (n=1839). The observations made 
in the EMC2 dataset (n=58; Figure 5A) are also apparent in the 
dataset containing all annotated cases of this GXB breast cancer 
instance (Figure 5B). Moreover, in this dataset it is clearly vis-
ible that IBS/IDS subgroups with an improved prognosis are more 
prevalent in the ICR4 cluster. For example, IBE-FID tumors are 
relatively more frequently assigned to ICR4 compared with IBD-
FID. Vice versa, IBD-PID tumors are proportionally more fre-
quently observed in the ICR1 cluster compared with IBE-PID 
tumors, which are in comparison more frequently assigned to 
ICR2 ICR3.
The overlay of the different immune classifications 
demonstrates a coherency between the IBS/IDS classification 
and the ICR clusters. Bearing in mind that the ICR signature is 
associated with a broader phenomenon of immune-mediated, 
tissue-specific destruction, this coherency strengthens the hypoth-
esis of a common final pathway of tissue destruction.
Conclusions
In this data note, we highlighted the opportunities provided 
by the availability of public datasets. We uploaded 13 public 
datasets on human breast cancer, including a combined dataset, 
with harmonized clinical data annotation and immune 
classification to GXB to facilitate the reuse of gene expression 
data. The use of GXB to explore gene expression and the different 
possible approaches were illustrated by the following: (1) an 
example case of a specific gene of interest, HLA-G; (2) com-
parison of gene expression between specific subgroups, IBD-FID 
vs IBE-FID; and (3) the evaluation of the relationship between 
different categorical variables, IBS/IDS and ICR immune 
classifications. To conclude, GXB provides a convenient environ-
ment to explore gene expression profiles in the context of breast 
cancer.
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The primary goal of this data note was to share the transcriptomic and annotation data
associated with this previous publication (in GXB defined as “the Nagalla 2013
reconstituted public dataset”) and the breast cancer transcriptomic datasets from GEO
that it constitutes of in a more interactive, comprehensible format to facilitate usage of the
data and did not involve data processing. The selection of 22,268 probe sets, combination
and normalization of the 13 datasets was also previously performed (Nagalla et al). For
your second point, we indeed meant the probe sets that are present in all platforms, for
this reasons probe sets that are exclusively present in Affymetrix U133 PLUS2.0 are not






The uploads from individual GEO datasets into GXB did not involve any data processing.
For the Nagalla et al this has been performed as part of the work described in Nagalla et
al. This data note did involve clinical data harmonization performed in R, scripts have
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When uploading these GEO datasets into GXB, all available clinical data on GEO was also
transferred to GXB. For some of the datasets (e.g. GSE4922), a treatment parameter is
available which can be selected as a parameter using the overlay function in the bar plot
generated in GXB. We completely agree that information on adjuvant treatment is
essential for interpretation of the supplied survival data (Distant Metastasis Free Survival
and Disease Free Survival). For proper survival analysis, we recommend users to
download the csv file supplied which can be found under the “Downloads”-tab of each
dataset and use available treatment information for stratification.
Addition of more gene signatures can indeed be valuable to compare immune based
classifications as demonstrated in this data note for Immunological Constant of Rejection
(ICR) classification and Immune Benefit Status (IBS)/ Immune Disposition Status (IDS).
Similarly, uploading additional GEO datasets that contain matched primary and metastatic
samples would be very interesting and allow for comparison of both immune
microenvironments. Although not in the scope of the current data note, we will definitely
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It is indeed possible to visualize the expression of a gene of interest, for example HLA-G,
in a specific subgroup of samples like all ER-negative or basal cases. The most
convenient way to do this is to (1) select barplot, (2) set group by Molecular Subtype and
(3) overlay the barplots with ICR group annotation. To make the figure easier to analyze,
you can subsequently sort by ICR. 
- It would be useful to provide tools for correlational analysis of two or more genes (e.g.
co-expression patterns) and heat maps. The one gene at a time visualization is very restrictive.
We realize that gene per gene visualization has its limitations and analysis of groups
coordinately expressed genes provides more biological significance. For this reason, the
GXB development team has already created a  module analysis tool (MAT) that analyses
expression data to find pre-defined groupings of co-expressed genes (modules) to obtain
a molecular fingerprint of gene expression for each individual sample in your dataset.
MAT has already been applied to many datasets with samples of various immune related
diseases and we are considering to also use this platform for cancer transcriptomic
datasets. As the desired number of group comparisons in breast cancer (i.e., Molecular
Subtypes, Immunologic classifications, Pathology T Stage) is higher compared to the
existing group comparisons, some work is required before we can implement these






We have added the suggested table to the manuscript. This is both useful when reading







These different HLA-G transcripts are indeed different probe sets. If you are interested to
find and select a specific probe ID, you can select “Show Probe ID” under “Tools”. This
GXB data portal does not give an explanation on the difference between these probes. For
this information we would like to refer to the Affymetrix website.  For the HLA-G example,
we just took a single probe at random: 211528_X_AT. We added this information in
version 2 of the manuscript.
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Names of datasets have been changed from “Princess Margaret Cancer Centre dataset -
GSE6532.GPL96” and “Princess Margaret Cancer Centre dataset - GSE6532.GPL97”, to
“John Radcliff Hospital (OXFU, OXFT) dataset- GSE6532.GPL96” and “John Radcliff
Hospital (OXFU, OXFT) dataset- GSE6532.GPL97” respectively. “Princess Margaret
Cancer dataset- GSE6532.GPL570” was changed to “Guys hospital (GUYT) dataset-




Thank you for noticing this. Only a single disease type can be assigned per dataset. We
can change ER+ and LN- datasets to disease type: Breast Cancer , effectively disabling
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can change ER+ and LN- datasets to disease type: Breast Cancer , effectively disabling
the user to filter datasets based on ER+ and LN status. We preferred changing the name





We were able to reproduce the barplot you described. By sorting by the categorical
variable DMFS 10Y EVENT, you only sort based on this variable (DistantMetastasisFree or
DistantMetastasis). The continuous counterpart of this variable (DMFS 10Y TIME) is not
taken into account when you perform the sorting, explaining your observation. An
alternative is to sort based on the continuous variable DMFS 10Y TIME, though this
sorting results in a plot that mixes DistantMetastasisFree and DistantMetastasis
categories. Unfortunately, subsequent sorting based on 2 variables is not possible using




Survival statistics are not yet part of the GXB web-application. To prevent any
misconception, we have added an extra sentence in the legend of figure 1: “This figure is





The purpose of this data note is to share existing data from GEO in a more
comprehensible format and does not involve any data processing. We had to make an







Normalization of the complete Nagalla cohort was previously performed as described in
Nagalla et al. 2013 and Miller et al. 2016 To make this data available as published in this
 article, we used the same data file to upload to GXB. Normalization is different between
datasets because the data was transferred straight from GEO and different contributors





 In this dataset collection, it is indeed possible to first explore the Nagalla dataset, which
is a dataset that includes all samples from the collection. This advantage is specific for
this breast cancer compendium of datasets, so your suggestion is a very good strategy to
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this breast cancer compendium of datasets, so your suggestion is a very good strategy to
explore these datasets. We have added this recommendation in the text of the Dataset






Categorization using the PAM50 molecular subtyping was performed as part of the
research performed by Nagalla et al. 2013 and Miller et al. 2016. These annotated datasets
were uploaded in GXB as described in this data note. The choice to rely on this 50-gene
classifier was dependent on its high prognostic and predictive value of this subtyping
method in combination with the high clinical applicability of PAM50 testing.  
Minor comments
Table 2 would be better represented as a barplot or a similar figure.
For the purpose of listing which clinical variables are available in how many datasets from




Comparing healthy control tissue with cancerous tissue on gene expression level indeed
represents an interesting aspect that can be explored using the GXB browser. At this
moment, different types of dataset collections have already been uploaded to GXB,
including case versus control comparisons. For example, a dataset with gene expression
of whole blood samples from both  lung cancer patients and healthy controls and a
dataset with head and neck cancer and cervical cancer tissue samples, matched with
site-matched normal epithelial samples are currently available. The TCGA, METABRIC
dataset and datasets in the GTEx portal are valuable resources that can be used to upload
new datasets into GXB. We will definitely take this suggestion into consideration for our
new dataset collection to upload into GXB.
 Discussed changes will be applied in version 2 of the manuscript.
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